Stoke Therapeutics (NASDAQ:STOK) Earns “Buy” Rating from HC Wainwright

HC Wainwright restated their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK) in a research note issued to investors on Wednesday morning, Benzinga reports. The firm currently has a $35.00 price target on the stock.

STOK has been the topic of several other research reports. Wedbush reaffirmed an outperform rating and set a $17.00 price objective on shares of Stoke Therapeutics in a research report on Thursday, July 11th. Needham & Company LLC restated a buy rating and set a $22.00 price target on shares of Stoke Therapeutics in a report on Thursday, August 8th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, Stoke Therapeutics presently has an average rating of Moderate Buy and an average price target of $21.40.

Stoke Therapeutics Trading Up 5.5 %

NASDAQ STOK opened at $14.47 on Wednesday. Stoke Therapeutics has a 1-year low of $3.35 and a 1-year high of $17.58. The firm’s fifty day simple moving average is $14.38 and its 200-day simple moving average is $12.91. The company has a market capitalization of $754.19 million, a PE ratio of -6.00 and a beta of 0.96.

Stoke Therapeutics (NASDAQ:STOK) last issued its earnings results on Wednesday, August 7th. The company reported ($0.46) earnings per share for the quarter, topping the consensus estimate of ($0.57) by $0.11. The company had revenue of $4.83 million for the quarter, compared to analyst estimates of $3.33 million. Stoke Therapeutics had a negative return on equity of 57.89% and a negative net margin of 683.35%. As a group, analysts predict that Stoke Therapeutics will post -2.18 EPS for the current year.

Insider Buying and Selling at Stoke Therapeutics

In other news, insider Barry Ticho sold 10,000 shares of the business’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $13.75, for a total value of $137,500.00. Following the completion of the sale, the insider now directly owns 2,485 shares in the company, valued at $34,168.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 11.30% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

A number of institutional investors have recently made changes to their positions in STOK. Nisa Investment Advisors LLC grew its holdings in Stoke Therapeutics by 53.2% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,989 shares of the company’s stock valued at $40,000 after buying an additional 1,038 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Stoke Therapeutics by 5.5% during the first quarter. Price T Rowe Associates Inc. MD now owns 31,431 shares of the company’s stock worth $425,000 after acquiring an additional 1,642 shares during the period. The Manufacturers Life Insurance Company increased its position in Stoke Therapeutics by 16.7% during the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company’s stock worth $189,000 after acquiring an additional 1,994 shares during the period. Quest Partners LLC acquired a new position in Stoke Therapeutics during the 2nd quarter valued at $29,000. Finally, Los Angeles Capital Management LLC boosted its holdings in Stoke Therapeutics by 7.2% in the 2nd quarter. Los Angeles Capital Management LLC now owns 66,765 shares of the company’s stock valued at $902,000 after purchasing an additional 4,508 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.